Novel Approaches in Primary Cardiovascular Disease Prevention : The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
8 p.
- Autores:
-
Lonn, Eva
Bosch, Jackie
Pogue, Janice
Avezum, Alvaro
Chazova, Irina
Dans, Antonio
Diaz, Rafael
Fodor, George J.
Held, Claes
Jansky, Petr
Keltai, Matyas
Keltai, Katalin
Kunti, Kamlesh
Kim, Jae Hyung
Leiter, Lawrence A.
Lewis, Basil S.
Liu, Lisheng
Lopez-Jaramillo, Patricio
Pais, Prem
Parkhomenko, Alexander
Peters, Ron J.G.
Piegas, Leopoldo S.
Reid, Christopher M.
Sliwa, Karen
Toff, William D.
Varigos, John
Xavier, Denis
Yusoff, Khalid
Zhu, Jun
Dagenais, Gilles
Yusuf, Salim
The HOPE-3 Investigators
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2016
- Institución:
- Universidad de Santander
- Repositorio:
- Repositorio Universidad de Santander
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.udes.edu.co:001/3472
- Acceso en línea:
- https://repositorio.udes.edu.co/handle/001/3472
- Palabra clave:
- Cardiovascular Disease Prevention
Cholesterol
Blood pressure
- Rights
- openAccess
- License
- Derechos Reservados - Canadian Journal of Cardiology, 2016
| id |
RUDES2_b6a51feff99133884c2dc07ff7af3514 |
|---|---|
| oai_identifier_str |
oai:repositorio.udes.edu.co:001/3472 |
| network_acronym_str |
RUDES2 |
| network_name_str |
Repositorio Universidad de Santander |
| repository_id_str |
|
| dc.title.eng.fl_str_mv |
Novel Approaches in Primary Cardiovascular Disease Prevention : The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics |
| title |
Novel Approaches in Primary Cardiovascular Disease Prevention : The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics |
| spellingShingle |
Novel Approaches in Primary Cardiovascular Disease Prevention : The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics Cardiovascular Disease Prevention Cholesterol Blood pressure |
| title_short |
Novel Approaches in Primary Cardiovascular Disease Prevention : The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics |
| title_full |
Novel Approaches in Primary Cardiovascular Disease Prevention : The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics |
| title_fullStr |
Novel Approaches in Primary Cardiovascular Disease Prevention : The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics |
| title_full_unstemmed |
Novel Approaches in Primary Cardiovascular Disease Prevention : The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics |
| title_sort |
Novel Approaches in Primary Cardiovascular Disease Prevention : The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics |
| dc.creator.fl_str_mv |
Lonn, Eva Bosch, Jackie Pogue, Janice Avezum, Alvaro Chazova, Irina Dans, Antonio Diaz, Rafael Fodor, George J. Held, Claes Jansky, Petr Keltai, Matyas Keltai, Katalin Kunti, Kamlesh Kim, Jae Hyung Leiter, Lawrence A. Lewis, Basil S. Liu, Lisheng Lopez-Jaramillo, Patricio Pais, Prem Parkhomenko, Alexander Peters, Ron J.G. Piegas, Leopoldo S. Reid, Christopher M. Sliwa, Karen Toff, William D. Varigos, John Xavier, Denis Yusoff, Khalid Zhu, Jun Dagenais, Gilles Yusuf, Salim The HOPE-3 Investigators |
| dc.contributor.author.spa.fl_str_mv |
Lonn, Eva Bosch, Jackie Pogue, Janice Avezum, Alvaro Chazova, Irina Dans, Antonio Diaz, Rafael Fodor, George J. Held, Claes Jansky, Petr Keltai, Matyas Keltai, Katalin Kunti, Kamlesh Kim, Jae Hyung Leiter, Lawrence A. Lewis, Basil S. Liu, Lisheng Lopez-Jaramillo, Patricio Pais, Prem Parkhomenko, Alexander Peters, Ron J.G. Piegas, Leopoldo S. Reid, Christopher M. Sliwa, Karen Toff, William D. Varigos, John Xavier, Denis Yusoff, Khalid Zhu, Jun Dagenais, Gilles Yusuf, Salim The HOPE-3 Investigators |
| dc.subject.proposal.eng.fl_str_mv |
Cardiovascular Disease Prevention Cholesterol Blood pressure |
| topic |
Cardiovascular Disease Prevention Cholesterol Blood pressure |
| description |
8 p. |
| publishDate |
2016 |
| dc.date.issued.spa.fl_str_mv |
2016-03 |
| dc.date.accessioned.spa.fl_str_mv |
2019-07-29T12:38:23Z |
| dc.date.available.spa.fl_str_mv |
2019-07-29T12:38:23Z |
| dc.type.spa.fl_str_mv |
Artículo de revista |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_6501 |
| status_str |
publishedVersion |
| dc.identifier.doi.spa.fl_str_mv |
10.1016/j.cjca.2015.07.001 |
| dc.identifier.issn.spa.fl_str_mv |
0828-282X |
| dc.identifier.uri.spa.fl_str_mv |
https://repositorio.udes.edu.co/handle/001/3472 |
| identifier_str_mv |
10.1016/j.cjca.2015.07.001 0828-282X |
| url |
https://repositorio.udes.edu.co/handle/001/3472 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartof.eng.fl_str_mv |
Canadian Journal of Cardiology |
| dc.rights.spa.fl_str_mv |
Derechos Reservados - Canadian Journal of Cardiology, 2016 |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0/ |
| rights_invalid_str_mv |
Derechos Reservados - Canadian Journal of Cardiology, 2016 Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.source.spa.fl_str_mv |
https://www.sciencedirect.com/science/article/abs/pii/S0828282X15005127?via%3Dihub |
| institution |
Universidad de Santander |
| bitstream.url.fl_str_mv |
https://repositorio.udes.edu.co/bitstreams/ebb8e586-51c0-482c-baae-13401a2902de/download https://repositorio.udes.edu.co/bitstreams/383f2b80-f28a-4c06-a79c-414f0c555a53/download https://repositorio.udes.edu.co/bitstreams/fa1161a3-2536-476d-9cc3-235bc04a6228/download https://repositorio.udes.edu.co/bitstreams/f2f2b771-c02b-4397-b4ce-309887216e33/download https://repositorio.udes.edu.co/bitstreams/b24e6f08-503e-4fb8-a826-afa327389814/download https://repositorio.udes.edu.co/bitstreams/bf47837e-04be-48a5-b775-625b78e89733/download |
| bitstream.checksum.fl_str_mv |
d784fa8b6d98d27699781bd9a7cf19f0 0c9e952550ae558778effa7860c5cf30 8b5889b01603e81a7ef529c5621445ff 38623f7fc4796c3c705a6c7900e4d35e 38d94cf55aa1bf2dac1a736ac45c881c ab0ea1cb4d78bb72fdf40be7f47e0f0c |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Universidad de Santander |
| repository.mail.fl_str_mv |
soporte@metabiblioteca.com |
| _version_ |
1814159044088168448 |
| spelling |
Lonn, Eva7a977a4b-14e3-44cc-8057-933d424aaa9b-1Bosch, Jackie503f2202-0dda-463c-acc9-f5888e895278-1Pogue, Janiceda5c963c-440a-4bf6-981a-f2217b50fc1d-1Avezum, Alvaro8b920360-abb2-4ec8-b5ee-4e3f4e0b11eb-1Chazova, Irinace6fc484-15aa-401c-a370-8afcad931907-1Dans, Antoniof365ef5a-7610-4022-8485-31d6d3879cd6-1Diaz, Rafaelf2be4a74-501a-4e63-8bbd-965cbcf8c57b-1Fodor, George J.4e2c9e54-7090-4288-8ae6-eec3df4c7d30-1Held, Claes76b69ce8-c468-49c5-8d48-95a823d8b565-1Jansky, Petrbf8ec62a-6edc-439c-a698-2e4fa4172f04-1Keltai, Matyas65c5da4f-dca6-4e4f-aa9e-6c2ff81f2df9-1Keltai, Kataline6748cb0-125e-4199-9d27-8f14335aec02-1Kunti, Kamlesha3bb2664-32e3-45e3-b644-cb9bf1128185-1Kim, Jae Hyung02f6ce1a-0939-4a0d-9f08-bb2d131dcf4e-1Leiter, Lawrence A.bcdd3211-40b7-474d-9f6c-8a1051ceb9bf-1Lewis, Basil S.a8106b8e-2b4b-412e-90c7-4012b1272405-1Liu, Lishenga14adafe-ef37-42b0-8f5b-0de4ea71b0fc-1Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Pais, Prem5abdbf77-3c3f-4396-8634-83723aa215b9-1Parkhomenko, Alexander11fab1ea-f0f6-47e0-97e9-36e372b7e2f9-1Peters, Ron J.G.43007a97-9e31-41a5-a7fc-ce7357bd484f-1Piegas, Leopoldo S.0f1da4dd-76bd-4381-87fa-1e01066eee6f-1Reid, Christopher M.7d8a8211-12ad-464c-948d-16952b66144d-1Sliwa, Karen7ff2b80f-9412-4d65-99cd-7d01d5578687-1Toff, William D.97acb6df-c33b-45ad-b772-c52ac4aa7281-1Varigos, Johnedec3b03-87c5-454c-aec5-b2c04c91a9d9-1Xavier, Denis88c9cf48-fa3b-45c6-be03-2cc79e59289d-1Yusoff, Khalid933db13d-f5bb-4ea6-91a5-68eea1ca9ffc-1Zhu, Jund97cdbd2-6a82-430c-abfe-c978f085997e-1Dagenais, Gillesc865f015-4dc7-483d-9dae-132288d901f8-1Yusuf, Salim06a836b5-f5e3-41d9-a516-9cc46e5d7948-1The HOPE-3 Investigatorsad5cd98d-86e0-4739-a226-91ef50ed152c-12019-07-29T12:38:23Z2019-07-29T12:38:23Z2016-038 p.Résumé Introduction Il est possible de faire baisser efficacement et en toute sécurité le cholestérol et la pression artérielle (PA) avec les statines et les antihypertenseurs tout en réduisant de 20 à 30 % les manifestations cardiovasculaires majeures en l’espace de cinq ans chez les personnes à risque élevé. Les données obtenues dans les populations exposées à un risque plus faible sont néanmoins limitées. L’essai HOPE-3 (Heart Outcomes Prevention Evaluation-3) tâche de déterminer si l’abaissement du cholestérol à l’aide d’une statine, l’abaissement de la pression artérielle à l’aide de deux agents antihypertenseurs administrés à raison d’une faible dose et leur association permettent de réduire en toute sécurité les manifestations cardiovasculaires majeures chez les personnes exposées à un risque intermédiaire qui n’ont pas d’antécédents d’événements vasculaires et dont le taux de cholestérol et la PA se situent dans la moyenne. Méthodes Au total, 12 705 femmes et hommes, les unes âgées de 65 ans et plus et les autres de 55 ans et plus, qui présentent au moins un facteur de risque cardiovasculaire et qui n’ont pas de maladie cardiovasculaire connue ni aucune indication ou contre-indication claires aux médicaments à l’étude, ont été répartis aléatoirement pour recevoir de la rosuvastatine à raison de 10 mg par jour ou un placebo et l’association candésartan/hydrochlorothiazide à raison de 16/12,5 mg par jour ou un placebo (plan factoriel 2 × 2). Ces patients seront suivis pendant une moyenne de 5,8 ans. Les principaux paramètres d’évaluation de l’étude combinent le décès d’origine cardiovasculaire, l’infarctus du myocarde non mortel et l’AVC non mortel d’une part, et le décès d’origine cardiovasculaire, l’infarctus du myocarde non mortel, l’AVC non mortel, la réanimation après arrêt cardiaque, l’insuffisance cardiaque et la revascularisation artérielle d’autre part. Résultats Les participants ont été recrutés dans 21 pays situés en Amérique du Nord, en Amérique du Sud, en Europe, en Asie et en Australie. L’âge moyen au moment de la répartition aléatoire était de 66 ans, et 46 % des sujets étaient des femmes. Conclusions L’essai HOPE-3 fournira de nouveaux renseignements sur l’abaissement du taux de cholestérol et de la PA dans des populations exposées à un risque intermédiaire dont le taux de cholestérol et la PA se situent dans la moyenne. Il devrait également fournir des données à l’appui des stratégies de prévention primaire mises en place partout dans le monde (HOPE-3 ClinicalTrials.gov NCT00468923).Cholesterol and blood pressure (BP) can be effectively and safely lowered with statin drugs and BP-lowering drugs, reducing major cardiovascular (CV) events by 20%-30% within 5 years in high-risk individuals. However, there are limited data in lower-risk populations. The Heart Outcomes Prevention Evaluation-3 (HOPE-3) trial is evaluating whether cholesterol lowering with a statin drug, BP lowering with low doses of 2 antihypertensive agents, and their combination safely reduce major CV events in individuals at intermediate risk who have had no previous vascular events and have average cholesterol and BP levels. Methods A total of 12,705 women 65 years or older and men 55 years or older with at least 1 CV risk factor, no known CV disease, and without any clear indication or contraindication to the study drugs were randomized to rosuvastatin 10 mg/d or placebo and to candesartan/hydrochlorothiazide 16/12.5 mg/d or placebo (2 × 2 factorial design) and will be followed for a mean of 5.8 years. The coprimary study outcomes are the composite of CV death, nonfatal myocardial infarction (MI), and nonfatal stroke and the composite of CV death, nonfatal MI, nonfatal stroke, resuscitated cardiac arrest, heart failure, and arterial revascularization. Results Participants were recruited from 21 countries in North America, South America, Europe, Asia, and Australia. Mean age at randomization was 66 years and 46% were women. Conclusions The HOPE-3 trial will provide new information on cholesterol and BP lowering in intermediate-risk populations with average cholesterol and BP levels and is expected to inform approaches to primary prevention worldwide (HOPE-3 ClinicalTrials.gov NCT00468923).application/pdf10.1016/j.cjca.2015.07.0010828-282Xhttps://repositorio.udes.edu.co/handle/001/3472engCanadian Journal of CardiologyDerechos Reservados - Canadian Journal of Cardiology, 2016info:eu-repo/semantics/openAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_abf2https://www.sciencedirect.com/science/article/abs/pii/S0828282X15005127?via%3DihubCardiovascular Disease PreventionCholesterolBlood pressureNovel Approaches in Primary Cardiovascular Disease Prevention : The HOPE-3 Trial Rationale, Design, and Participants' Baseline CharacteristicsArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85PublicationTEXTNovel Approaches in Primary Cardiovascular Disease Prevention. The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.pdf.txtNovel Approaches in Primary Cardiovascular Disease Prevention. The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.pdf.txtExtracted texttext/plain2https://repositorio.udes.edu.co/bitstreams/ebb8e586-51c0-482c-baae-13401a2902de/downloadd784fa8b6d98d27699781bd9a7cf19f0MD56BRANDED_PREVIEWNovel Approaches in Primary Cardiovascular Disease Prevention. The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.PNG.preview.jpgNovel Approaches in Primary Cardiovascular Disease Prevention. The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.PNG.preview.jpgGenerated Branded Previewimage/jpeg6046https://repositorio.udes.edu.co/bitstreams/383f2b80-f28a-4c06-a79c-414f0c555a53/download0c9e952550ae558778effa7860c5cf30MD54THUMBNAILNovel Approaches in Primary Cardiovascular Disease Prevention. The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.PNG.jpgNovel Approaches in Primary Cardiovascular Disease Prevention. The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.PNG.jpgUDESimage/jpeg1590https://repositorio.udes.edu.co/bitstreams/fa1161a3-2536-476d-9cc3-235bc04a6228/download8b5889b01603e81a7ef529c5621445ffMD53Novel Approaches in Primary Cardiovascular Disease Prevention. The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.pdf.jpgNovel Approaches in Primary Cardiovascular Disease Prevention. The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.pdf.jpgGenerated Thumbnailimage/jpeg1462https://repositorio.udes.edu.co/bitstreams/f2f2b771-c02b-4397-b4ce-309887216e33/download38623f7fc4796c3c705a6c7900e4d35eMD57LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/b24e6f08-503e-4fb8-a826-afa327389814/download38d94cf55aa1bf2dac1a736ac45c881cMD52ORIGINALNovel Approaches in Primary Cardiovascular Disease Prevention. The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.pdfNovel Approaches in Primary Cardiovascular Disease Prevention. The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.pdfapplication/pdf239122https://repositorio.udes.edu.co/bitstreams/bf47837e-04be-48a5-b775-625b78e89733/downloadab0ea1cb4d78bb72fdf40be7f47e0f0cMD55001/3472oai:repositorio.udes.edu.co:001/34722023-10-10 08:38:54.623https://creativecommons.org/licenses/by-nc/4.0/Derechos Reservados - Canadian Journal of Cardiology, 2016https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo= |